Purpose Great heterogeneity exists in the ability of adults with cancer to tolerate chemotherapy. Variability in body composition may affect rates of metabolism of cytotoxic agents and contribute to the variable chemotherapy toxicity observed. The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer. Methods We performed a secondary analysis of a completed multicenter trial that investigated PK-guided 5FU dosing in patients receiving mFOLFOX6 +/− bevacizumab for colorectal cancer. Cycle 1 PK samples were obtained 2-44 h after the start of the 5FU infusion (steady state).
Introduction
Heterogeneity exists in the ability of adults with cancer to tolerate chemotherapy. In metastatic colorectal cancer (CRC), chemotherapy is complicated by the high incidence and large individual variability in toxicity, particularly in older adults [1, 2] . To minimize the risk of adverse outcomes, there is a critical need to understand the causes of such variability in chemotherapy toxicity.
Differences in body composition may underlie some of the heterogeneity in chemotherapy toxicity by altering chemotherapy distribution, metabolism, and clearance [3] . A wide distribution of lean body mass (LBM) is seen for any given body weight, which is not accounted for by conventional chemotherapy dosing by body surface area (BSA) [3] . In aging, loss of skeletal muscle and increases in adiposity result in a lower LBM relative to overall body weight, thus potentially causing a lower volume of distribution and higher drug concentrations. Low muscle mass, commonly known Previously presented as a poster at the Gastrointestinal Cancers Symposium, San Francisco, CA January 20th, 2017. as sarcopenia, is highly prevalent in adults with cancer [4] . Low muscle mass in adults with CRC is associated with an increased risk for chemotherapy toxicity and shorter survival [5, 6] . Low LBM relative to BSA may account for increased toxicities observed in sarcopenic patients [3, 5] . Our primary objective was to explore the association of sarcopenia (low muscle mass) and 5-fluorouracil (5FU) pharmacokinetics (PKs) in patients receiving FOL-FOX ± bevacizumab for CRC. We hypothesized that patients with sarcopenia would have higher 5FU exposure, measured as area-under-the-concentration-time-curve-(AUC), and increased chemotherapy toxicities.
Materials and methods
We performed a secondary analysis of a multicenter trial of PK-guided 5FU dosing in patients receiving mFOLFOX6 +/− bevacizumab for CRC [7] . All patients received mFOL-FOX6 at cycle 1: oxaliplatin 85 mg/m 2 over 2 h, leucovorin 200-400 mg/m 2 over 2 h, 5FU 400 mg/m 2 bolus, and 5FU 2400 mg/m 2 over 46 h (via a battery operated pump) with or without bevacizumab. Cycle 1 PK samples were obtained 2-44 h after the start of the 5FU infusion (steady state). AUC analysis was conducted by Myriad Genetics, Inc. via nanoparticle-based immuno-assay. The target AUC range of infusional 5FU was 20-25 mg × h/L [7] . Toxicity was measured using the NCI CTCAE v3.0 during cycles 1-4.
Abdominal computed tomography (CT) scans performed as part of usual care prior to chemotherapy administration were used to examine body composition. The transverse section at the L3 vertebral level was identified and extracted for analysis using the automated image segmentation software [8] . The L3 landmark was used as it has been identified as the strongest predictor of whole body fat and fat-free mass when compared to dual-energy X-ray absorptiometry (DXA) [9, 10] . The software recognizes muscle tissue based on density thresholds and provides an unbiased estimation of the cross-sectional skeletal muscle area (SMA). Images were reviewed and corrected for accuracy by trained study personnel. Measured SMA was normalized for square height to calculate a skeletal muscle index (SMI) (cm 2 /m 2 ) using the following formula: (skeletal muscle area-cm 2 )/(patient height-m 2 ). Sarcopenia was defined using gender and BMI cutoffs from Martin et [6] . We chose these specific cutoffs as they were derived from a large population of patients with gastrointestinal cancers and their frequent use in the oncology literature. We estimated total LBM using the following formula: [LBM (kg) = 0.30 × [skeletal muscle at L3 using CT (cm 2 )] + 6.06] [5] .
This study was approved by the IRB at the University of North Carolina (IRB-16-0124) and study procedures were in accordance with the ethical standards of the responsible committee on human experimentation.
Statistical analyses
For the primary objective, incidence of chemotherapy toxicity and 5FU AUCs was compared between sarcopenic and non-sarcopenic patients using two group t tests and Fisher's exact tests. We also examined the association between 5FU dose per estimated LBM (mg infusional 5FU/kg LBM) [5] with severe toxicities. Poisson regression models with a robust variance estimator were used to estimate unadjusted relative risks with 95% confidence intervals. All analyses were conducted using the SAS v9.4 statistical software (Cary, NC).
Results
Of the 70 patients from the original study, we obtained CT images for 25 participants. The mean age was 59 years, 52% female, and 80% Caucasian ( Table 1 ). The mean dose of 5FU per kg LBM was 90 mg/kg (range 50-154 mg/kg). The average first cycle AUC for 5FU was 18 (range 7-31), and The last figure demonstrates the differences in 5FU dose/LBM for the patients within the various AUC ranges (d) the majority of patients were under the target therapeutic range (64% with AUC < 20). Twelve patients were sarcopenic (48%). Although sarcopenic patients had a statistically higher dose of 5FU/LBM compared to non-sarcopenic patients (110 vs. 87.5 mg/kg, p = 0.0087), no significant differences in first cycle 5FU AUCs were found (17.3 vs. 19.3 AUC, p = 0.43).
Eleven patients (44%) had grade 3/4 toxicity, including 28% with hematologic and 28% with non-hematologic, during the first four cycles. Sarcopenic patients were more likely to experience grade 3/4 toxicities (50% vs. 39%, p = 0.70). Patients with grade 3/4 toxicity also had a higher average dose of 5FU/LBM (105 vs. 93 mg/kg, p = 0.058), which was more pronounced in hematological toxicities (110 vs. 94 mg/ kg, p = 0.002) than non-hematological (100 vs. 98 mg/kg, p = 0.75) (Fig. 1) . There was no difference in 5FU/LBM between AUC categories (Fig. 1) .
In an unadjusted model, for every 10 mg/kg increase in the dose of 5FU/LBM, the relative risk of any grade 3/4 toxicities was 1.15 (95% CI 1.0-1.3), 1.29 (95% CI 1.1-1.5) for grade 3/4 hematological toxicity, and 1.04 (95% CI 0.8-1.3) for grade 3/4 non-hematological toxicities.
Discussion
In this exploratory study, sarcopenic patients with CRC trended towards higher incidence of severe grade 3/4 toxicities; however, there was no difference in first cycle 5FU AUCs. Higher doses of infusional 5FU per LBM were associated with more severe chemotherapy toxicity, but not with 5FU AUC. Although our findings were not able to confirm the impact of low skeletal muscle on PKs, we believe that this warrants further evaluation given the growing evidence that LBM dosing may be superior to conventional BSA dosing for drugs that are distributed and metabolized in lean tissue [3] . This is likely particularly relevant for older adults in whom sarcopenia is highly prevalent [11] .
Variability in 5FU PKs is widely recognized [7] ; this is partially explained by genotype differences in dihydropyrimidine dehydrogenase (DPD) [12] , the metabolizing enzyme of 5FU, and differences in distribution and clearance based on age, sex, organ function, and diet [13] . The limited sample size and limited PK analysis (which did not include peak concentration, clearance, or volume of distribution) of this exploratory analysis preclude definitive conclusions about the contribution of these factors to our findings.
Changes in body composition as a result of aging and cancer cachexia are not accounted for by traditional BSA dosing and may contribute to the variability in treatment outcomes in cancer [3] . Explicit evaluation of the impact of muscle mass on chemotherapy drug levels is needed to better understand the relationship between sarcopenia and chemotherapy toxicity and may lead to an individualized dosing strategy that reduces toxicity while maintaining efficacy.
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